Luminex Corporation Company Profile (NASDAQ:LMNX)

About Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation logoLuminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LMNX
  • CUSIP: 55027E10
  • Web:
  • Market Cap: $928.6 million
  • Outstanding Shares: 43,926,000
Average Prices:
  • 50 Day Moving Avg: $20.71
  • 200 Day Moving Avg: $19.54
  • 52 Week Range: $17.64 - $23.75
  • Trailing P/E Ratio: 65.90
  • Foreward P/E Ratio: 33.68
  • P/E Growth: 0.72
Sales & Book Value:
  • Annual Revenue: $285.44 million
  • Price / Sales: 3.27
  • Book Value: $9.51 per share
  • Price / Book: 2.23
  • Annual Dividend: $0.24
  • Dividend Yield: 1.1%
  • EBIDTA: $50.46 million
  • Net Margins: 5.00%
  • Return on Equity: 5.48%
  • Return on Assets: 4.98%
  • Current Ratio: 5.79%
  • Quick Ratio: 4.34%
  • Average Volume: 227,173 shs.
  • Beta: 0.35
  • Short Ratio: 6.88

Frequently Asked Questions for Luminex Corporation (NASDAQ:LMNX)

What is Luminex Corporation's stock symbol?

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex Corporation pay dividends? What is the dividend yield for Luminex Corporation?

Luminex Corporation declared a quarterly dividend on Thursday, May 25th. Shareholders of record on Friday, June 23rd will be given a dividend of $0.06 per share on Friday, July 14th. This represents a $0.24 annualized dividend and a yield of 1.13%. The ex-dividend date is Wednesday, June 21st. View Luminex Corporation's Dividend History.

How were Luminex Corporation's earnings last quarter?

Luminex Corporation (NASDAQ:LMNX) released its quarterly earnings data on Monday, May, 1st. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.12. The business earned $77.80 million during the quarter, compared to analyst estimates of $74.25 million. Luminex Corporation had a return on equity of 5.48% and a net margin of 5.00%. The business's revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.29 earnings per share. View Luminex Corporation's Earnings History.

Where is Luminex Corporation's stock going? Where will Luminex Corporation's stock price be in 2017?

6 brokers have issued 1-year price targets for Luminex Corporation's stock. Their predictions range from $18.00 to $27.00. On average, they anticipate Luminex Corporation's stock price to reach $21.40 in the next year. View Analyst Ratings for Luminex Corporation.

What are analysts saying about Luminex Corporation stock?

Here are some recent quotes from research analysts about Luminex Corporation stock:

  • 1. According to Zacks Investment Research, "Over the past one year, Luminex outperformed the broader industry in terms of price performance. The company operates in a highly competitive life sciences industry, which is likely to mar its growth trajectory in the coming quarters. Reduced spending on research and diagnostics by Luminex’ partner companies are adversely impacting the demand for the company’s products of late. Luminex may be impacted by future changes to the reimbursement landscape in the molecular diagnostic market. Luminex reported stable first-quarter 2017 results, beating the Zacks Consensus Estimates on both lines. Onthe positive side, the company’s Assay business will be its key growth driver over the long term. We are also optimistic about the company’s products – ARIES and NxTAG RPP – which represent a major revenue opportunity." (5/4/2017)
  • 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Who are some of Luminex Corporation's key competitors?

Who are Luminex Corporation's key executives?

Luminex Corporation's management team includes the folowing people:

  • G. Walter Loewenbaum II, Independent Chairman of the Board
  • Nachum Shamir, President, Chief Executive Officer, Director
  • Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer
  • Richard W. Rew II, Senior Vice President, General Counsel, Secretary
  • Nancy M. Fairchild, Senior Vice President - Human resources
  • Randall Myers, Senior Vice President - Global Manufacturing and Quality
  • Robert J. Cresci, Independent Director
  • Stephen L Eck, Independent Director
  • Thomas Willard Erickson, Independent Director
  • Jimmy Dale Kever, Independent Director

Who owns Luminex Corporation stock?

Luminex Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.36%), VILLERE ST DENIS J & COMPANY LLC (8.93%), Villere ST Denis J & Co. LLC (9.31%), Vanguard Group Inc. (8.42%), RGM Capital LLC (6.63%) and Dimensional Fund Advisors LP (4.20%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Russell W Bradley. View Institutional Ownership Trends for Luminex Corporation.

Who sold Luminex Corporation stock? Who is selling Luminex Corporation stock?

Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Kalmar Investments Inc. DE, Acadian Asset Management LLC, Great Lakes Advisors LLC, American Century Companies Inc., Bank of Montreal Can, Wells Fargo & Company MN, Eos Focused Equity Management L.P. and Russell Investments Group Ltd.. Company insiders that have sold Luminex Corporation stock in the last year include G Walter Loewenbaum II and Kevin M Mcnamara. View Insider Buying and Selling for Luminex Corporation.

Who bought Luminex Corporation stock? Who is buying Luminex Corporation stock?

Luminex Corporation's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., RGM Capital LLC, Elk Creek Partners LLC, Renaissance Technologies LLC, Blair William & Co. IL, Vanguard Group Inc., State Street Corp and Neuberger Berman Group LLC. Company insiders that have bought Luminex Corporation stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex Corporation.

How do I buy Luminex Corporation stock?

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex Corporation's stock price today?

One share of Luminex Corporation stock can currently be purchased for approximately $21.22.

MarketBeat Community Rating for Luminex Corporation (NASDAQ LMNX)
Community Ranking:  1.1 out of 5 ()
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  243
MarketBeat's community ratings are surveys of what our community members think about Luminex Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Luminex Corporation (NASDAQ:LMNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $21.40 (0.85% upside)

Analysts' Ratings History for Luminex Corporation (NASDAQ:LMNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/9/2017Jefferies Group LLCReiterated RatingHold$21.00LowView Rating Details
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
2/7/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016J P Morgan Chase & CoUpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
8/4/2015WedbushUpgradeNeutral -> Outperform$19.00 -> $22.00N/AView Rating Details
7/1/2015Cowen and CompanyBoost Price TargetMarket Perform$17.00 -> $18.00N/AView Rating Details
(Data available from 6/27/2015 forward)


Earnings History for Luminex Corporation (NASDAQ:LMNX)
Earnings by Quarter for Luminex Corporation (NASDAQ:LMNX)
Earnings History by Quarter for Luminex Corporation (NASDAQ LMNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Luminex Corporation (NASDAQ:LMNX)
2017 EPS Consensus Estimate: $0.24
2018 EPS Consensus Estimate: $0.45
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.06$0.06$0.06
Q3 20171$0.06$0.06$0.06
Q4 20171$0.03$0.03$0.03
Q1 20181$0.12$0.12$0.12
Q2 20181$0.11$0.11$0.11
Q3 20181$0.11$0.11$0.11
Q4 20181$0.11$0.11$0.11
(Data provided by Zacks Investment Research)


Current Dividend Information for Luminex Corporation (NASDAQ:LMNX)
Next Dividend:7/14/2017
Annual Dividend:$0.24
Dividend Yield:1.13%
Payout Ratio:75.00% (Trailing 12 Months of Earnings)
43.64% (Based on This Year's Estimates)
38.10% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Luminex Corporation (NASDAQ:LMNX)

Dividend History by Quarter for Luminex Corporation (NASDAQ LMNX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Luminex Corporation (NASDAQ:LMNX)
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 77.18%
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/30/2017G Walter Loewenbaum IIDirectorSell25,000$20.07$501,750.00View SEC Filing  
5/23/2017G Walter Loewenbaum IIDirectorSell25,000$20.23$505,750.00View SEC Filing  
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.00View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.00View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.00View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.00View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.02View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.53View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Luminex Corporation (NASDAQ:LMNX)
Latest Headlines for Luminex Corporation (NASDAQ:LMNX)
DateHeadline logoConforMIS (CFMS) Gets FDA Approval for iTotal Hip System - June 26 at 9:24 AM logoEvolent Health (EVH) Prices 4.5M Follow-On Share Offering - June 23 at 7:46 AM logoETFs with exposure to Luminex Corp. : June 19, 2017 - June 19 at 5:21 PM logoDENTSPLY (XRAY) Renews Partnership with Pacific Dental - June 19 at 11:49 AM logoLuminex Corp. :LMNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 16 at 7:14 PM logoCONMED (CNMD) Hits a 52-Week High: What's Driving the Stock? - June 14 at 10:24 AM logoLuminex Corporation (LMNX) Given Average Rating of "Hold" by Analysts - June 13 at 12:50 PM logoZacks: Brokerages Anticipate Luminex Co. (LMNX) Will Announce Quarterly Sales of $75.18 Million - June 10 at 8:24 AM logoLuminex Co. (LMNX) Rating Reiterated by Jefferies Group LLC - June 9 at 5:08 PM logoLuminex Co. (LMNX) Expected to Announce Earnings of $0.11 Per Share - June 8 at 4:30 PM logoFeatured Company News - Luminex's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan - June 7 at 9:29 AM logoLuminex Corporation's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan - June 5 at 9:45 AM logoPatterson Companies Grapples With Multiple Issues: Dump Now? - June 2 at 7:43 PM logoG Walter Loewenbaum II Sells 25,000 Shares of Luminex Co. (LMNX) Stock - June 1 at 4:29 PM logoThermo Fisher on an Acquisition Spree, Competition Rife - May 30 at 10:14 AM logoVarian Medical at a 52-Week High: What's Driving the Stock? - May 30 at 10:14 AM logoInogen (INGN) Hits a 52-Week High on Solid Q1, Upbeat View - May 30 at 10:14 AM logoNuVasive Aims for Innovation, Global Growth amid Woes - May 30 at 10:14 AM logoQuintiles IMS Holdings (Q) to Repurchase 10.6M Common Share - May 30 at 10:14 AM logoIDEXX Laboratories Global Growth Solid amid Currency Woes - May 30 at 10:14 AM logoLuminex Co. (LMNX) to Issue $0.06 Quarterly Dividend - May 25 at 6:50 PM logoLuminex Co. (LMNX) Director G Walter Loewenbaum II Sells 25,000 Shares - May 25 at 1:22 PM logoLuminex Corporation Declares Second Quarter Cash Dividend - May 24 at 11:07 AM logoIntegra LifeSciences to Offer aap's LOQTEQ System in the US - May 24 at 11:07 AM logoLabCorp Offers Sera's PreTRM to Assess Preterm Birth Risk - May 24 at 11:07 AM logoLuminex Co. (LMNX) Upgraded by TheStreet to "B-" - May 23 at 5:34 PM logoBruker Corp (BRKR) at 52-Week High: What's Driving the Stock? - May 23 at 10:43 AM logoIDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects - May 23 at 10:43 AM logoHologic (HOLX) Poised on Balanced Growth Amid Currency Woes - May 23 at 10:43 AM logoIntuitive Surgical at 52-Week High: What's Driving the Stock? - May 22 at 10:20 AM logoLuminex Co. (LMNX) Receives Consensus Recommendation of "Hold" from Brokerages - May 19 at 12:52 PM logoHalyard Health Announces New Drainage System, Stock Down - May 18 at 8:54 AM logoGenomic Health's (GHDX) Oncotype DX GPS Test Data Positive - May 16 at 10:43 AM logoCR Bard (BCR) Hits a 52-Week High: What's Driving the Stock? - May 15 at 10:35 AM logoLuminex Co. (LMNX) Expected to Post Quarterly Sales of $75.18 Million - May 14 at 9:24 AM logo$0.08 EPS Expected for Luminex Co. (LMNX) This Quarter - May 12 at 2:16 PM logoLuminex Co. (LMNX) Rating Increased to Hold at ValuEngine - May 11 at 11:28 PM logoZacks Investment Research Upgrades Luminex Co. (LMNX) to "Strong-Buy" - May 4 at 1:54 PM logoQ2 2017 Earnings Forecast for Luminex Co. (LMNX) Issued By Jefferies Group - May 4 at 12:34 PM logoLuminex (LMNX) Given Daily News Sentiment Rating of 0.22 - May 3 at 8:56 PM logoLuminex Corporation Receives FDA Clearance for ARIES Bordetella Assay - May 3 at 5:25 PM logoLuminex Co. (LMNX) to Post FY2018 Earnings of $0.99 Per Share, William Blair Forecasts - May 3 at 5:14 PM logoQ3 2017 Earnings Forecast for Luminex Co. (LMNX) Issued By Jefferies Group - May 3 at 10:54 AM logoLuminex Co. (LMNX) Given Hold Rating at Jefferies Group LLC - May 2 at 7:46 PM logoEdited Transcript of LMNX earnings conference call or presentation 1-May-17 8:30pm GMT - May 2 at 12:36 PM logoBiotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals - May 2 at 12:36 PM logoLuminex Co. (LMNX) Issues Earnings Results, Beats Expectations By $0.12 EPS - May 1 at 11:38 PM logoLuminex Corporation Reports Record First Quarter 2017 Financial Results; Raises 2017 Financial Guidance - May 1 at 5:22 PM logoLuminex beats Street 1Q forecasts - May 1 at 5:22 PM logoVery Positive News Coverage Extremely Likely to Impact Luminex (LMNX) Share Price - April 30 at 9:26 AM



Luminex Corporation (LMNX) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by Staff